Neoadjuvant SBRT followed by evorpacept and pembrolizumab in HPV-mediated head and neck squamous cell carcinoma: Investigation of pathologic response.
Joseph A. Califano(University of California San Diego), R. Bryan Bell(Takara (United States)), Robert Saddawi‐Konefka(The University of Texas MD Anderson Cancer Center), Kyaw Zin Thein(Oregon Health & Science University), Ryan J. Li(Oregon Health & Science University), Thomas Duhen(AGCO (Netherlands)), Andrew B. Sharabi(UC San Diego Health System), Kristina H. Young(Providence Portland Medical Center), Rom S. Leidner(Providence Portland Medical Center), Karen Messer(Human Longevity (United States)), Тимур Митин(Oregon Health & Science University), Brian Piening(Providence College), Xinlian Zhang(University of California San Diego), Liza Blumenfeld(UC San Diego Health System), Ezra E.W. Cohen(Moores Cancer Center), Steven K. Seung(Providence Portland Medical Center), Marka R. Crittenden(Providence Portland Medical Center)
Cited by 0
Related Papers
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
|Nature Communications|2018|927